Drug Induced Rheumatological Disease AND Biologics Safety

The answer first

Drug-induced rheumatological disease is a heterogeneous group of iatrogenic immune syndromes — drug-induced lupus (DIL), TNF-inhibitor-induced lupus, immune-checkpoint-inhibitor (CPI) inflammatory arthritis and myositis, interferon-induced lupus, and vasculitis — that share three features: a defined drug trigger, immune-mediated pathology, and a clinical strategy of drug withdrawal plus targeted anti-inflammatory therapy. The "biologics safety" companion topic covers the predictable harms of these powerful immunomodulators: serious infection, reactivation of latent tuberculosis and hepatitis B, demyelination, heart failure, cytopenias, hypersensitivity, and the specific issues of conception, pregnancy and lactation. The FRACP candidate must recognise the syndromes, withdraw or switch the offending agent, and counsel the patient on the risk-benefit profile of any subsequent biologic. ^{[1] [12]}

The consultant-level decision sequence is: (1) confirm the temporal relationship between drug exposure and the rheumatological syndrome; (2) exclude idiopathic disease and infection; (3) withdraw the offending drug if at all possible; (4) treat the immune phenotype (NSAIDs, hydroxychloroquine, corticosteroids, methotrexate, or a more targeted agent); and (5) plan a safe alternative long-term therapy in conjunction with the prescribing oncologist, dermatologist or gastroenterologist when the trigger is essential. ^{[2] [11]}

References10ShowHide

1. [1]Pandey SN, Babu MA, Goyal K, Menon SV, et al. Targeting NLRP3 inflammasome with curcumin: mechanisms and therapeutic promise in chronic inflammation Inflammopharmacology, 2025.PMID 40928616
2. [2]Dans-Caballero S, Cecchi I, Radin M, Sciascia S JAK inhibitors for the management of rheumatic diseases when antiphospholipid syndrome co-exists: case-based safety considerations Lupus, 2025.PMID 40393677
3. [3]Sciascia S, Foddai SG, Arbrile M, Radin M, et al. Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review Immunol Res, 2024.PMID 38459403
4. [7]D'Gama JD, Bermas BL Safety of biologic agents for the management of rheumatic diseases during pregnancy Curr Opin Rheumatol, 2024.PMID 38456470
5. [8]Sánchez-García V, Hernández-Quiles R, de-Miguel-Balsa E, Giménez-Richarte Á, et al. Exposure to biologic therapy before and during pregnancy in patients with psoriasis: Systematic review and meta-analysis J Eur Acad Dermatol Venereol, 2023.PMID 37262303
6. [9]Panne I, Matter M, Vosbeck J, von Rotz M, et al. Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor Front Immunol, 2026.PMID 42375372
7. [10]Sun Y, Liu J, He M, Chen X Baicalin improves the inflammatory response of RA-FLS by targeting the circ_0000734/miR-197-5p/IKBKB axis Front Immunol, 2026.PMID 42292404
8. [11]Tison A, Jannat-Khah D, Cappelli LC, Suarez-Almazor ME, et al. Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study J Immunother Cancer, 2026.PMID 42208976
9. [12]Borchers AT, Keen CL, Gershwin ME Drug-induced lupus Ann N Y Acad Sci, 2007.PMID 17893983
10. [13]Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade N Engl J Med, 2016.PMID 27806233